Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGENDA trial of dacarbazine with or without Genasense in advanced melanoma
ISRCTN34237167Phase 3Completed
- Sponsor
- Genta Incorporated
- Start
- Jul 2007
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Dacarbazine + Genasense with Dacarbazine + placebo (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jul 2007; status: completed.
02
Drugs
oblimersendacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on ISRCTN34237167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN34237167.